Whan In Pharm Co.,Ltd. (016580.KS)
KRW 11930.0
(-0.33%)
KRW 11930.0
(-0.33%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 43.01 Billion KRW | 21.36% |
| 2022 | 35.44 Billion KRW | -1.44% |
| 2021 | 35.96 Billion KRW | 9.12% |
| 2020 | 32.95 Billion KRW | 8.33% |
| 2019 | 30.42 Billion KRW | 8.26% |
| 2018 | 28.1 Billion KRW | -11.5% |
| 2017 | 31.75 Billion KRW | 36.22% |
| 2016 | 23.31 Billion KRW | -18.08% |
| 2015 | 28.45 Billion KRW | -2.96% |
| 2014 | 29.32 Billion KRW | 47.43% |
| 2013 | 19.89 Billion KRW | 5.25% |
| 2012 | 18.89 Billion KRW | 16.26% |
| 2011 | 16.25 Billion KRW | 34.53% |
| 2010 | 12.08 Billion KRW | 14.96% |
| 2009 | 10.5 Billion KRW | 7.93% |
| 2008 | 9.73 Billion KRW | -13.11% |
| 2007 | 11.2 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 52.05 Billion KRW | -1.87% |
| 2024 Q1 | 53.04 Billion KRW | 23.31% |
| 2023 FY | 43.01 Billion KRW | 21.36% |
| 2023 Q4 | 43.01 Billion KRW | 7.0% |
| 2023 Q3 | 40.2 Billion KRW | -3.94% |
| 2023 Q2 | 41.85 Billion KRW | -8.13% |
| 2023 Q1 | 45.55 Billion KRW | 28.53% |
| 2022 Q3 | 30.96 Billion KRW | 14.29% |
| 2022 Q2 | 27.09 Billion KRW | -20.57% |
| 2022 FY | 35.44 Billion KRW | -1.44% |
| 2022 Q4 | 35.44 Billion KRW | 14.47% |
| 2022 Q1 | 34.1 Billion KRW | -5.15% |
| 2021 Q3 | 30.22 Billion KRW | -2.3% |
| 2021 FY | 35.96 Billion KRW | 9.12% |
| 2021 Q1 | 33.85 Billion KRW | 2.73% |
| 2021 Q2 | 30.93 Billion KRW | -8.63% |
| 2021 Q4 | 35.96 Billion KRW | 18.99% |
| 2020 FY | 32.95 Billion KRW | 8.33% |
| 2020 Q1 | 33.46 Billion KRW | 9.99% |
| 2020 Q2 | 29.18 Billion KRW | -12.79% |
| 2020 Q3 | 32.32 Billion KRW | 10.78% |
| 2020 Q4 | 32.95 Billion KRW | 1.95% |
| 2019 Q1 | 36.82 Billion KRW | 31.03% |
| 2019 FY | 30.42 Billion KRW | 8.26% |
| 2019 Q4 | 30.42 Billion KRW | 7.69% |
| 2019 Q3 | 28.25 Billion KRW | -1.42% |
| 2019 Q2 | 28.65 Billion KRW | -22.17% |
| 2018 Q2 | 25.17 Billion KRW | -28.72% |
| 2018 FY | 28.1 Billion KRW | -11.5% |
| 2018 Q4 | 28.1 Billion KRW | 1.05% |
| 2018 Q3 | 27.81 Billion KRW | 10.47% |
| 2018 Q1 | 35.31 Billion KRW | 11.22% |
| 2017 FY | 31.75 Billion KRW | 36.22% |
| 2017 Q3 | 24.66 Billion KRW | 2.37% |
| 2017 Q4 | 31.75 Billion KRW | 28.73% |
| 2017 Q1 | 25.42 Billion KRW | 9.05% |
| 2017 Q2 | 24.09 Billion KRW | -5.21% |
| 2016 Q1 | 31.71 Billion KRW | 11.47% |
| 2016 Q3 | 20.23 Billion KRW | -23.22% |
| 2016 Q4 | 23.31 Billion KRW | 15.18% |
| 2016 FY | 23.31 Billion KRW | -18.08% |
| 2016 Q2 | 26.35 Billion KRW | -16.9% |
| 2015 Q4 | 28.45 Billion KRW | 8.87% |
| 2015 Q1 | 34.5 Billion KRW | 17.66% |
| 2015 Q3 | 26.13 Billion KRW | -8.55% |
| 2015 Q2 | 28.58 Billion KRW | -17.16% |
| 2015 FY | 28.45 Billion KRW | -2.96% |
| 2014 Q4 | 29.32 Billion KRW | 49.15% |
| 2014 FY | 29.32 Billion KRW | 47.43% |
| 2014 Q3 | 19.66 Billion KRW | 2.58% |
| 2014 Q2 | 19.16 Billion KRW | -17.98% |
| 2014 Q1 | 23.36 Billion KRW | 17.47% |
| 2013 Q4 | 19.89 Billion KRW | 21.04% |
| 2013 FY | 19.89 Billion KRW | 5.25% |
| 2013 Q1 | 23.46 Billion KRW | 24.18% |
| 2013 Q2 | 17.27 Billion KRW | -26.37% |
| 2013 Q3 | 16.43 Billion KRW | -4.89% |
| 2012 Q1 | 20.37 Billion KRW | 25.36% |
| 2012 Q4 | 18.89 Billion KRW | 6.28% |
| 2012 Q2 | 21.06 Billion KRW | 3.39% |
| 2012 FY | 18.89 Billion KRW | 16.26% |
| 2012 Q3 | 17.78 Billion KRW | -15.59% |
| 2011 Q2 | 19.4 Billion KRW | 0.26% |
| 2011 Q1 | 19.35 Billion KRW | 60.16% |
| 2011 Q3 | 16.83 Billion KRW | -13.22% |
| 2011 FY | 16.25 Billion KRW | 34.53% |
| 2011 Q4 | 16.25 Billion KRW | -3.46% |
| 2010 Q3 | 11.28 Billion KRW | 0.84% |
| 2010 Q2 | 11.19 Billion KRW | -23.46% |
| 2010 Q4 | 12.08 Billion KRW | 7.07% |
| 2010 Q1 | 14.62 Billion KRW | 39.11% |
| 2010 FY | 12.08 Billion KRW | 14.96% |
| 2009 Q3 | 10.05 Billion KRW | -10.14% |
| 2009 FY | 10.5 Billion KRW | 7.93% |
| 2009 Q2 | 11.18 Billion KRW | -16.77% |
| 2009 Q1 | 13.44 Billion KRW | 38.04% |
| 2009 Q4 | 10.5 Billion KRW | 4.54% |
| 2008 Q2 | 11.18 Billion KRW | -21.78% |
| 2008 Q3 | 10.44 Billion KRW | -6.6% |
| 2008 Q4 | 9.73 Billion KRW | -6.76% |
| 2008 FY | 9.73 Billion KRW | -13.11% |
| 2008 Q1 | 14.29 Billion KRW | 27.56% |
| 2007 Q3 | 11.41 Billion KRW | -0.28% |
| 2007 Q4 | 11.2 Billion KRW | -1.78% |
| 2007 FY | 11.2 Billion KRW | 0.0% |
| 2007 Q1 | 12.97 Billion KRW | 0.0% |
| 2007 Q2 | 11.44 Billion KRW | -11.8% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | 44.747% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 95.373% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 93.916% |
| HANDOK Inc. | 449.7 Billion KRW | 90.434% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | 49.785% |
| Yuhan Corporation | 712.33 Billion KRW | 93.961% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 93.192% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -170.655% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 94.95% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | 19.633% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 79.104% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | 42.772% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | 70.893% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | 38.894% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | 44.747% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -18.067% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 82.871% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | 80.508% |
| JW Holdings Corporation | 827.51 Billion KRW | 94.801% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 90.156% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 92.669% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 88.667% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | 45.752% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | 38.516% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | 82.286% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 86.976% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | 44.747% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 91.221% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 94.986% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 88.667% |
| Yuhan Corporation | 712.33 Billion KRW | 93.961% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 90.997% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | 68.592% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 91.674% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 88.667% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | 72.162% |
| Korea United Pharm Inc. | 89.96 Billion KRW | 52.183% |
| CKD Bio Corp. | 170.76 Billion KRW | 74.807% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 82.35% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | 72.713% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | 45.752% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 93.199% |
| Boryung Corporation | 373.1 Billion KRW | 88.47% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | 79.337% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 79.104% |
| JW Lifescience Corporation | 96.44 Billion KRW | 55.394% |